UBS Group’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-2,378
| Closed | -$125K | – | 9187 |
|
|
2020
Q3 | $125K | Sell |
2,378
-1,837
| -44% | -$76K | ﹤0.01% | 5061 |
|
|
2020
Q2 | $140K | Sell |
4,215
-29,809
| -88% | -$949K | ﹤0.01% | 5061 |
|
|
2020
Q1 | $925K | Sell |
34,024
-36,615
| -52% | -$1.02M | ﹤0.01% | 3416 |
|
|
2019
Q4 | $1.39M | Sell |
70,639
-46,775
| -40% | -$748K | ﹤0.01% | 3904 |
|
|
2019
Q3 | $1.52M | Buy |
117,414
+112,223
| +2,162% | +$1.36M | ﹤0.01% | 3574 |
|
|
2019
Q2 | $65K | Buy |
5,191
+2,824
| +119% | +$37.5K | ﹤0.01% | 5696 |
|
|
2019
Q1 | $34K | Sell |
2,367
-72,015
| -97% | -$920K | ﹤0.01% | 5855 |
|
|
2018
Q4 | $821K | Buy |
74,382
+70,882
| +2,025% | +$987K | ﹤0.01% | 3860 |
|
|
2018
Q3 | $92K | Buy |
3,500
+3,055
| +687% | +$82.6K | ﹤0.01% | 5665 |
|
|
2018
Q2 | $9K | Sell |
445
-89,756
| -100% | -$1.93M | ﹤0.01% | 7220 |
|
|
2018
Q1 | $1.64M | Buy |
90,201
+87,997
| +3,993% | +$1.47M | ﹤0.01% | 3301 |
|
|
2017
Q4 | $31K | Sell |
2,204
-2,591
| -54% | -$35K | ﹤0.01% | 6219 |
|
|
2017
Q3 | $89K | Buy |
4,795
+1,536
| +47% | +$25.7K | ﹤0.01% | 5388 |
|
|
2017
Q2 | $55K | Buy |
3,259
+1,096
| +51% | +$16.7K | ﹤0.01% | 5585 |
|
|
2017
Q1 | $29K | Sell |
2,163
-34,729
| -94% | -$544K | ﹤0.01% | 5893 |
|
|
2016
Q4 | $555K | Buy |
36,892
+26,669
| +261% | +$352K | ﹤0.01% | 4028 |
|
|
2016
Q3 | $120K | Sell |
10,223
-2,870
| -22% | -$33.7K | ﹤0.01% | 4896 |
|
|
2016
Q2 | $142K | Sell |
13,093
-1,658
| -11% | -$17.1K | ﹤0.01% | 4789 |
|
|
2016
Q1 | $136K | Sell |
14,751
-71,471
| -83% | -$769K | ﹤0.01% | 4762 |
|
|
2015
Q4 | $1.28M | Buy |
86,222
+69,794
| +425% | +$1.17M | ﹤0.01% | 3203 |
|
|
2015
Q3 | $270K | Sell |
16,428
-30,579
| -65% | -$626K | ﹤0.01% | 4398 |
|
|
2015
Q2 | $1.07M | Buy |
47,007
+24,015
| +104% | +$478K | ﹤0.01% | 3508 |
|
|
2015
Q1 | $350K | Sell |
22,992
-106,987
| -82% | -$1.39M | ﹤0.01% | 4418 |
|
|
2014
Q4 | $1.56M | Buy |
+129,979
| New | +$1.49M | ﹤0.01% | 3141 |
|
UBS Group's MNTA Position: Q4 2020 in Review
UBS Group sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q4 2020, closing a stake of 2,378 shares — an estimated $125K sold.
UBS Group first reported a position in MNTA in Q4 2014 and held it in 24 quarters. The position peaked at $1.64M in Q1 2018. 0 funds tracked by Wall St. Rank hold MNTA as of Q4 2020.
- UBS Group reported no remaining Momenta Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
- UBS Group sold 2,378 Momenta Pharmaceuticals, Inc. shares in Q4 2020, an estimated $125K.
- UBS Group first reported a position in Momenta Pharmaceuticals, Inc. in Q4 2014 and held it in 24 quarters.
- UBS Group's Momenta Pharmaceuticals, Inc. position peaked at $1.64M in Q1 2018.
- 0 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q4 2020.
Based on UBS Group's 13F filing for Q4 2020, filed 11 Feb 2021.